1 KASP-PCR method to screen thrombophilia genetic risk

2 factors

3

4 Reham Altwayan^{1,2}, Huseyin Tombuloglu^{2*}, Abdulrahman Alhusil³, Taghreed

- 5 Awadh³, Mona Altwayan³, Heba Albaqawi³, Noof Aldossary³, Turgay Unver⁴
- 6

7 ¹Master Program of Biotechnology, Institute for Research and Medical Consultations, Imam

- 8 Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- 9 ²Department of Genetics Research, Institute for Research and Medical Consultations (IRMC),
- 10 Imam Abdulrahman Bin Faisal University, 31441, Dammam, Saudi Arabia
- 11 ³Department of Internal Medicine, King Fahad Military Medical Complex, Dhahran, Saudi
- 12 Arabia
- ⁴Department of Computer Engineering, Ostim Technology University, Ankara, Turkey
- 14
- 15 <u>*htoglu@iau.edu.sa</u>
- 16

17 Abstract

18 Thrombophilia is defined as the willingness of blood to clot easily in a situation of 19 imbalances between fibrinolysis and coagulation. It is classified as inherited and 20 acquired thrombophilia. Several studies revealed that the inherited thrombophilia is 21 strongly associated with single nucleotide polymorphisms (SNP) or deletions on certain 22 genes, such as FV Leiden (rs6025), MTHFR1 (rs1801133), MTHFR2 (rs1801131), 23 Serpine-1 (rs1799768), and Factor II (rs1799963). This study aims to develop an SNP 24 detection panel based on Kompetitive Allele Specific Primer-polymerase chain reaction 25 (KASP-PCR) technique. Results revealed that 86.5% of susceptible patients (n = 111) 26 contain at least one mutation; while seven of them harbor three thrombophilia-associated 27 mutations simultaneously. A clear allelic discrimination was observed for all tested 28 samples. The prevalence of each mutation among different countries and ethnic groups 29 are in line with the findings of this study. Rather than expensive and time-consuming 30 approaches, the current assay enables the cost-effective advantage of the KASP-PCR, 31 which reduces the diagnostic cost with a fast and convenient way. After clinical 32 validation and approval, it can be used in hospitals, research centers, and diagnostic 33 laboratories to determine the genetic susceptibility of individuals to thrombosis and for 34 research purposes.

35

36 Keywords: SNP, thrombophilia, prevalence, molecular diagnosis, mutation.

37

38 Introduction

39 Thrombophilia is defined by the World Health Organization/International Society of 40 Thrombosis and Hemostasis (WHO/ISTH) as an abnormal tendency to coagulation or 41 clotting of the blood in a part of the circulatory system (WHO, 1995). The disease poses 42 a significant health burden. According to the CDC reports, >900,000 people in the 43 United States alone are affected by blood clots each year, with substantial mortality 44 rates. Due to thrombophilia-related complications, 60,000 to 100,000 deaths are 45 recorded in the USA annually, which is greater than the total number of people who lose 46 their lives each year from AIDS, breast cancer, and motor vehicle crashes combined 47 (Badireddy & Mudipalli, 2022). The disease is classified as inherited and acquired

thrombophilia. Inherited thrombophilia is associated with four SNPs and one deletion
mutations located in different genes, namely: coagulation *factor II (FII), coagulation factor V (FV), 5,10- methylene tetrahydrofolate reductase (MTHFR1* and *MTHFR2),*and *serpine1 (SERPINE1)* (Yapijakis et al, 2015).

52 Diagnostic approaches include detecting disorders by examining clinical signs, 53 imaging techniques, and analysis through molecular aspects. Direct DNA genotyping, 54 PCR-based techniques, immunological detection, and chromogenic assays are used to 55 identify thrombophilia-related disorders (Linnemann and Hart 2019). Sequencing 56 techniques are the most accurate approaches followed and used for validation purposes. 57 On the other hand, PCR-based approaches such as TaqMan, KASP and rhAmp are 58 mostly used due to their simplicity, timesaving, cost-effectiveness, and ability to 59 measure the heterozygosity or homozygosity of mutations carried among thrombophilia 60 genes.

61 Kompetitive Specific Allele Primer-PCR (KASP-PCR) is a fluorescent-based 62 reporting system to identify and measure the SNPs (He et al., 2014). It is used to 63 differentiate between species in plants and animals (Yang et al., 2020). KASP-PCR 64 technique is fast, sensitive, relevant, and cost-effective (Alvarez-Fernandez et al., 2021; 65 Zhang et al., 2020). Due to the cost advantage, it has been applied widely in plant 66 breeding for commercial use (Makhoul et al., 2020). KASP technique is precise, and its 67 specificity is based on the competitive nature of allele specific forward primers and 68 modified Taq polymerase.

69 The current genotyping techniques are based on sequencing or PCR, which are 70 time consuming and expensive methods. Therefore, a cost-effective, time-saving, and 71 accurate technique is needed to screen symptomatic and asymptomatic suspicious 72 people. This study aims to screen thrombophilia associated SNPs based on KASP-PCR 73 technique. For this purpose, the DNA samples of thrombophilia-susceptible patients (n =74 111) were collected and five associated mutations on FV Leiden, MTHFR1, MTHFR2, 75 Serpine-1, and Factor II genes were identified. Rather than expensive and time-76 consuming approaches, the current assay reduces the diagnostic cost in a fast and 77 convenient way.

78

79 Material and Methods

80 Collection of blood samples and ethical concerns

5 mL of leftover whole blood samples were retrieved from King Fahad Military Medical Complex (KFMHC) (IRB Protocol No: AFHER-IRB-2022-031). A total of 111 samples have been collected from thrombophilia-susceptible patients who have been admitted to the hospital with thrombophilia symptoms, such as chest pain, abdominal pain, dizziness, fever, seizure, breath shortness, etc. The blood samples were collected in an Ethylenediamine tetra acetic acid tube (EDTA) and stored at -20 °C until DNA extraction.

88

89 Extraction of DNA

QIAamp® DNA Blood Mini Kit 250 (QIAGEN) was used to extract and purify DNA.
The instructions of the manufacturer were followed. The final eluate was kept at -20 °C
for further stages. NanoDropTM 2000/2000c spectrophotometer was used to quantify the
purity and concentration of extracted DNA samples. The samples were also visualized in
agarose gel for 20 min at 100 Volt and monitored under UV light (Molecular Imager®
ChemiDocTM XRS+, Bio-Rad). Image LabTM Software (Bio-Rad) was utilized to save
the images.

97

98 Primer design

99 Primers corresponding to the SNP positions were manually designed. First, the 100 NCBI corresponding gene sequences were retrieved from database 101 (https://www.ncbi.nlm.nih.gov) and Primer Blast tool was used to pick the primers. In 102 addition, Primer 3 program was used to verify the designed primers: one common 103 reverse, two alternating forward primers that are specific to the SNP positions.

104

105 Validation of plate reader and KASP-PCR reaction

Before genotyping, KASP genotyping validation kit (LOW ROX KASP TF Validation kit, LGC) was used to validate the plate-reader instrument (7500 Fast Real-Time PCR System). According to the manufacturer's protocol, the compatibility and readability of the plate reader was confirmed. The kit consists of three tubes of diluted fluorophores: FAM, HEX, and HEX/FAM. The tubes were briefly vortexed and dispensed into a microtiter plate. Then, KASP reagents (2x KASP master mix, and 72x KASP assay mix) with provided DNA samples (n = 36) were used to run the following protocol: (1) 94 °C

113 15 minutes for activation (1 cycle); (2) 94 °C 20 sec for denaturation and 61-55 °C 60 114 sec (drop 0.6 °C per cycle) for annealing/elongation (10 cycles); (3) 94 °C 20 sec for 115 denaturation and 55 °C 60 sec for annealing/elongation (26 cycles). At the end of the 116 reaction, the endpoint fluorescent reading was performed. To obtain the best genotyping 117 clusters, the plate underwent two rounds of recycle steps, as follows: 94 °C 20 sec for 118 denaturation, and 57 °C for 60 sec for annealing/elongation (3 cycles).

119

120 Genotyping of thrombophilia-associated SNPs with KASP-PCR

121 The KASP primer mixture for each target SNPs was prepared including 12 μ l of 122 forward-1 primer, 12 μ l of forward-2 primer, 30 μ l of common reverse primer, and 46 μ l 123 of distilled water to reach the total volume of 100 μ l. Then, 5 μ l of master mixture 124 (KASPTM TF Low ROX Master Mix) and 0.14 μ l of assay mixture were added and 125 vortexed briefly. In 96 well plate, 5 μ l of assay mixture was added with 5 μ l of DNA 126 sample in each well and then sealed tightly. The KASP genotyping assay was performed 127 by using real-time PCR 7500 (Applied Biosystem) instrument.

128

129 **RESULTS**

130 Calibration and optimization of KASP protocol

131 Before the KASP-PCR reaction for the discrimination of thrombophilia-associated 132 SNPs, the validity of the fluorescent thermal cycler and the protocol for KASP-PCR 133 were optimized and validated. Nine positive control samples (LGC Bioscience), labeled 134 with FAM (blue), HEX (red), and FAM/HEX (green) fluorophores, were used to 135 optimize, and verify the fluorescence signals that will be obtained from the thermal 136 cycler. Figure 1 depicts the cluster plot of FAM, HEX, and FAM/HEX labeled positive 137 control samples. The clusters correspond to homozygote dominant (allele 1/allele 1), 138 homozygote recessive (allele 2/allele 2), and heterozygote (allele 1/allele 2) 139 discriminations. This result showed optimized and successful KASP-PCR reaction 140 conditions with calibrated fluorometric measurements.



141

Figure 1. The allelic discrimination plot of FAM (blue), HEX (red) and FAM/HEX
(green) fluorophores. Three samples used for each positive control dyes.

144

145 Furthermore, the optimized protocol was used to discriminate real DNA samples 146 (n = 45) provided by the LOW ROX KASP TF Validation kit (LGC Biosciences). In 147 addition to the DNA samples, three negative control samples were included. After the 148 KASP-PCR reaction, the allelic discrimination plot was depicted in **Figure 2**. The results 149 were shown before (Figure2A) and after three (Figure2B) and six (Figure2C) additional 150 recycling stages. After six recycling stages, positive and negative samples were clearly 151 separated, and the negative control specimens were placed near the origin side of the plot. 152 In addition, the homozygote and heterozygote alleles were determined to be well-153 clustered. It is obvious that additional recycling steps improved the allelic discrimination, 154 where the best and most efficient results were obtained upon six additional recycling 155 stages (Figure 2C). 156



157

Figure 2. Validation of plate reader and KASP-PCR protocol. Allelic discrimination plot of DNA samples (n = 45). A) Without recycle step. B) After the addition of three recycling steps. C) After the addition of six recycling steps. Black dots indicate the negative control sample. Red, blue, and green dots indicate the homozygotes of Allele 1, homozygotes of Allele 2, and heterozygotes of Allele 1/2.

163

165 KASP-PCR genotyping of rs6025 (G1691A) on the Factor V Leiden gene

166 An optimized KASP-PCR protocol was performed to identify the G1691A substitution 167 on the FVL mutation (FV gene, rs6025). Figure 3. shows the discrimination plots of 168 samples. Since the total sample number (n = 111) is more than the capacity of the 169 thermal cycler (n = 96), the reaction was completed in two separate runs. Upon the 170 KASP-PCR reaction, an additional six recycling steps was added for the best reaction 171 performance. Black dots indicate negative control, green dots indicate heterozygote 172 sample (CT), and blue dots indicate homozygote (CC). Accordingly, only one sample 173 was detected as heterozygote (\sim 1%), and the rest of the samples were homozygote wild 174 (~99%). This result shows that almost all thrombophilia-susceptible individuals admitted 175 to the hospital are free of FVL gene mutation.

176



177

Figure 3. The figure shows the discrimination plot of FVL mutation with an additional 6
cycles. Black dots indicate negative control, green dot indicate heterozygote sample
(CT), and blue dots indicate homozygote wild (CC).

181

182 KASP-PCR genotyping of (rs1799963) (G20210A) on the FII gene

183 KASP-PCR assay was performed to screen the G20210A variation on the *FII-PT* gene.

184 Figure 4.1 depicts the discrimination plots of extracted DNA samples. Since the

185 capacity of the PCR plate is 96 wells, the run was divided into two runs. In addition to 186 the KASP-PCR thermal cycle, six more recycling step was added to improve 187 discrimination. Black dots refer to negative control, placed near the plot's origin side; 188 blue dots refer to homozygote wild samples (GG); red dot sample is homozygote mutant 189 (AA), while no green dots of heterozygote recorded. Only one sample was recorded as 190 homozygote recessive, while the rest of the sample was homozygote dominant, and no 191 heterozygote detected. This result shows that only one of the susceptible thrombophilia 192 patients carried the FII-PT mutation.

193





Figure 4.1 Shows the discrimination plot of *Factor II mutation* with an additional 6
cycles. Black dots indicate negative control, blue dots indicate homozygote wild (GG),
and red dots indicate homozygote mutant (AA).

198

199 KASP-PCR genotyping of (rs1801133) on the *MTHFR* gene

After optimization of the KASP-PCR assay, screening for mutation on *MTHFR1* was performed (*MTHFR* gene, rs1801133). **Figure 25** illustrates the discrimination plot of susceptible-thrombophilia patient samples. The reaction was completed in two runs due to the number of samples (n=111). In addition, six recycling steps were added to obtain clear discrimination. Four black dots refer to negative control and are correctly placed

205 near the origin of the plot, green dots refer to the heterozygote sample (CT), and red dots 206 refer to the homozygote sample (CC). Consequently, 24 % of the patients were 207 heterozygote, only two samples were recorded as homozygote recessive (TT) (~2%), 208 and the rest of the samples were recorded as homozygote dominant. This result shows 209 that ~26% of the patients admitted to the hospital with a risk of developing 210 thrombophilia are carrying at least one allele of *MTHFR1* mutation.

211





Figure 2. Shows the Allelic Discrimination Plot of *MTHFR* rs1801133 (C/T) mutation with an additional 6 cycles. Black dots indicate negative control; green dots indicate heterozygote (CT); and red dots indicate homozygote mutant (TT); blue dots indicate homozygote.

217

218 KASP-PCR genotyping of (rs1801131) on the *MTHFR2* gene

An optimized KASP-PCR assay was achieved to screen the mutation placed on the *MTHFR2* gene (rs1801131). **Figure 3** demonstrates the discrimination plot of two runs performed on extracted DNA samples. With the addition of six thermal recycling steps, the reaction shows the best performance. Black dots imply negative control; green dots imply heterozygote sample (AC), blue dots imply homozygote wild (AA), and red dots imply homozygote recessive (CC) alleles. Discrimination results showed that ~53% of

225 the patients admitted to the hospital are free of mutation (wild), 39% carrying this

226 mutation in one allele, and 6.3% carrying two alleles of mutation. The result shows that

- ~45% of susceptible thrombophilia patients have at least one mutation.
- 228



229

Figure 3. Shows the Allelic Discrimination Plot of *MTHFR* rs1801131 mutation with the addition of 3 cycles. Black dots indicate negative control; red dots indicate homozygote mutant (CC), green dots indicate heterozygote (AC), and blue dots indicate homozygote wild.

234

235 KASP-PCR genotyping of Serpine 1 (rs1799768)

236 Genetic screening for Serpine 1 (rs1799768) mutation was performed by optimized 237 KASP-PCR assay. Figure 7 shows the discrimination plot of the (n=111) sample 238 divided into two runs due to the capacity of the thermal cycler. Black dots indicate 239 negative control, and it is successfully placed near the origin of the plot; blue dots 240 indicate homozygote dominant 5G/5G, green dots indicate heterozygote 5G/4G and red 241 dots indicate homozygote recessive 4G/4G. Unlike other genes, only three additional 242 thermals are needed to obtain clear discrimination of samples. Therefore, 47 of the 243 sample was detected as homozygote dominant ($\sim 42\%$), 44 of the sample were detected 244 as heterozygote by carrying one mutation (~39%), and 17 were detected as homozygote

- 245 recessive (~15%). The result shows that more than 50% of patients harbor Serpine 1 246 mutation, which increases the risk of developing thrombophilia.
- 247



248

249 Figure 7. Shows the discrimination plot of Serpine 1 rs1799768 mutation with an 250 additional 3 cycles. Black dots indicate negative control, red dots indicate homozygote 251 mutant (4G/4G), green dots indicate heterozygote (5G/4G), and blue dots indicate 252 homozygote wild.

253

254 DISCUSSION

255 This study aims to screen genetic risk factors in patients susceptible to thrombophilia 256 disease by applying the cost-effective PCR technique (KASP-PCR). For this purpose, 257 left-over blood samples (n = 111) collected from thrombophilia symptomatic patients 258 were utilized for genetic screening. Approximately 30% of the cases were admitted to 259 the hospital with chest pain and 20% with abdominal pain. In addition to these 260 symptoms, vomiting (2.7%), shortness of breath (11%), palpitations (4.5%), dizziness 261 (10%), and fever (5.5%) were among the most common symptoms recorded. Patients 262 who apply to the hospital with suspicion of the disease are aged 5-92 (mean = 52), male 263 and female (62 male, 50 female).

264 KASP-PCR analyses revealed that 92 out of 111 (~83%) patients susceptible to 265 thrombophilia carry at least one of the analyzed mutations. The age and gender were not 266 found to be associated with thrombophilia-related polymorphisms (P > 0.05). Before 267 KASP-PCR genotyping testing, the KASP genotyping validation kit was used to 268 optimize and validate the plate reader. The device was calibrated according to the 269 passive reference dye ROXTM contained in the KASP master mixture. Optimal FAM, 270 HEX, and FAM/HEX fluorescence signals were checked and adjusted for the most 271 efficient signal score. Figure 1. shows successful discrimination in testing FAM, HEX, 272 and FAM/HEX dyes; where FAM is clustered in the Y-axis direction, HEX is clustered 273 in the X-axis opposite direction, while the FAM/HEX mixture is clustered in the middle. 274 Moreover, the cycle and re-cycling stages were optimized to obtain the best allelic 275 discrimination (Figure 2). Results revealed that two rounds of three re-cycling steps (six 276 in total) provided the most efficient protocol for robust allelic discrimination.

277 The primary role of the FV gene is regulating the production of coagulation 278 factor V protein. A mutation found in this gene (G1691A) substitutes arginine to 279 glutamine amino acid at point 506 in a polypeptide of Factor V (Arg506Gln) (Madkhaly 280 et al., 2021), leading to unresponsiveness to anticoagulant factors (C and S) (Kujovich, 281 2018). The risk of developing thrombophilia is five times higher in heterozygotes and 50 282 times higher in homozygotes, and it is responsible for 20-25% of all VTE cases (Bezgin 283 et al., 2018). It was found to be the most critical genetic risk factor related to 284 thrombophilia (Djordjevic et al., 2012). The prevalence of FVL among the European 285 population is high, while it is rare in Eastern Asia and Africa. Since the Arab countries 286 are geographically at the center. The prevalence of FVL mutation in different countries 287 and ethnic groups are listed in **Table 1**. Our results showed that all collected samples are 288 homozygote wild, except one sample which is heterozygote (No. 61). In **Figure 3.**, the 289 heterozygote individual was admitted to the hospital with flank pain and dysuria. A 290 prospective study aims to evaluate the prevalence of FVL in 149 healthy Saudi subjects 291 revealed that 2% of the individuals are heterozygotes, and none of those individuals are 292 homozygotes mutant (0%) (Almawi et al., 2005). Golestani et al., (2022) investigated 293 the correlation between acute myocardial infarction (AMI) and FVL in the Iranian 294 population; 5.5% of cases were found to be heterozygotes, while 1% were homozygote 295 mutants. On the other hand, Gowda et al., (2000) found that among American subjects,

- 8% were heterozygote. Based on these results, the data in the literature is in line with
- and compatible with our results.
- 298 Table 1 The prevalence of thrombophilia-associated SNPs according to different
- 299 countries, ethnic groups, and this study.

Factor V	Genotype	Saudi	Caucasia	Asia	Lebanon	Tunisia	Bahrain	Saudi
Leiden		Arabia						Arabia
	G/A	5.5%	7.5%	0%	13.8%	5.8%	3%	0.9%
	A/A	0.39%	0.2%	0%	1%	0.6%	0%	0%
	GG	94.11%	92.3%	100%	85.2%	93.6%	97%	99.1%
Reference		Madkhaly	Raptopoulou	Madkhaly	Almawi	Almawi	Almawi	This study
		et al, 2021	et al, 2022	et al, 2021	et al.,	et al.,	et al.,	
					2005	2005)	2005	

300

Factor II	Genotype	Saudi Arabia	Caucasia	Asia	Jordan	Bahrain	Chechan	Saudi Arabia
		¹ ii ubiu						muonu
	G/A	2.8%	4.1%	0.8%	5.7%	1%	1%	0%
	A/A	0.09%	0.2%	0%	2%	0%	0%	1%
	G/G	97.11%	95.7%	99.2%	92.3%	99%	99%	99%
Reference		Madkhaly	Madkhaly	Gunathilake	Al-	Almawi	Dajani et	This
		et al, 2021	et al, 2021	et al, 2015	Zoubi et	et al.,	al., 2012	study
					al.,	2005		
					2021			

	Genotype	Saudi Arabia	Caucasia	Asia	Jordan	African America n	Lebanon	Saudi Arabia
MTHFR	C/T	24%	49.3%	45%	%38	%26	30%	24%
I	T/T	2.5%	35.9%	22%	10%	2.7%	4%	2%
	C/C	73.5%	14.8%	33%	52%	71.3%	66%	74%
MTHFR	A/C	39%	40%	44%	50%	27%	50%	40%
П	C/C	10%	11.5%	5%	12%	3.6%	24%	6%
	A/A	51%	48.5%	51%	38%	69.4%	26%	54%
Reference		AlGasham	Raptopoul	Wang et al	Yousef	Graydon	Sabbagh et	This
		et al, 2011	ou et al,	2016	et al,	et al,	al, 2008	study
			2021		2013	2019		

Serpine-1	Genotype	Saudi	Caucasia	Asia	Jordan	UK	Turkey	Saudi Arabia
		Arabia						
	4G/5G	33.6%	51%	55%	39%	43%	40%	41%
	4G/4G	7.7%	23%	26%	27%	26%	26%	16%
	5G/5G	58.7%	26%	29%	34%	31%	34%	43%
Reference		Settin et al,	Nikolopo	Xu et	Al-Zoubi	Balta et al.	Balta et al.	This study
		2012	ulos et al,	al.	et al.,	2003	2003	
			2014	2016	2021			

302

303

304 *Prothrombin* is a protein synthesized in the liver and is essential in clotting the 305 blood (Khan & Dickerman, 2006). As a result of the replacement of guanine with 306 adenine at position 20210 of the coagulation factor II (FII) gene (G20210A), high 307 concentrations of prothrombin protein are activated (Poudel et al., 2020; Ahmed et al., 308 2020; Rennert & DeSimone, 2019). An increase in prothrombin level increases thrombin 309 level and inhibits Activated Protein C (APC) - inhibits FV protein-, subsequently 310 stimulating thrombus formation. Thus, the risk of VTE appearance increases. It is 311 estimated to be the second most important genetic risk factor causing thrombophilia 312 (Djordjevic et al., 2012). In our experiment, one out of 90 patients carry a homozygous 313 mutant allele (Patient No. 52, 86 years old male, and suffering from dysuria); no 314 mutation was detected in other samples (Figure 4.14). A study has been conducted to 315 screen *FII* and *FVL* mutations from eight years-old patient who is suffering from dysuria 316 and priapism. The genotyping result revealed that the patient was heterozygote for both 317 mutations (Özbek et al., 2003). At the same time, the patient is homozygote with FII and 318 heterozygote with FVL. A retrospective study showed that 2.6% of patients screened for 319 FII are positive through Saudi thrombosis patients (Madkhaly et al., 2021). A cross 320 sectional study investigate the prevalence of FII mutation in Jordanian population; 5.7% 321 were heterozygote while 2% were homozygote mutant (Al-Zoubi et al., 2021). A group 322 of healthy Arab population enrolled in a retrospective study to test the distribution of 323 FII. No mutated allele among Saudis was observed, while 1% of heterozygotes in 324 Bahraini. In Lebanese and Tunisian, 3.6% and 2.6% are heterozygotes, respectively 325 (Almawi et al., 2005). An amplification refractory mutation detection system (ARMS) 326 was applied to define the prevalence of *FII* in Chechans populations in Jordan; only 2% 327 of heterozygotes were detected, while no homozygote mutant (Dajani et al., 2012). The

fact that the mutation prevalence in the general population is 2-3% in the western region,
while rare in other geographical regions and all previous literature shows a rare
incidence of FII mutation, which reflects KASP-PCR results.

331 The *MTHFR* gene decreases homocysteine concentration by producing the 332 MTHFR enzyme to convert the homocysteine to methionine (Hickey et al., 2013; Dean, 333 2016). Two recognized mutations in the MTHFR gene inactivate the enzyme, leading to 334 increased levels of homocysteine and decreased levels of folate in plasma: C677T 335 (rs1801133) and A1286C (rs1801131) (Dölek et al., 2007). The American Congress of 336 Obstetricians and Gynecologists recommends screening for MTHFR mutations instead 337 of homocysteine concentration in patients at risk of thrombophilia (Hickey et al., 2013). 338 In our experiment, we detected these mutations using KASP-PCR method. The 339 prevalence of C677T (rs1801133) was ~2% with homozygote mutant, ~24% 340 heterozygote, and ~75% homozygote wild (Figure 25). Whereas the prevalence of 341 A1286C (rs1801131) was ~6% homozygote, ~40% heterozygote, and ~55% 342 homozygote wild (Figure 36). The prevalence of C677T among Hispanics is over 25% 343 and between 10-15% among Caucasians and North Americans with homozygote type 344 (Hickey et al., 2013). Dajani et al, (2013). Investigating the prevalence of C677T among 345 Chechen and Circassians healthy individuals; 27.5% of Chechen carry the mutation, 346 while 50% of Circassians. A study reported that 31% of patients with stroke carried 347 heterozygosity of C677T, while 15% were homozygote mutants. The higher incidence of 348 that variant is attributed to other risk factors, such as smoking and hypertension 349 (Djordjevic et al., 2012).

350 A variation in the *serpine 1* gene is represented by the deletion of 4G/5G alleles 351 in position 675 in chromosome 7 at the promoter region (Xu et al., 2016; Isordia-Salas et 352 al., 2009; Tsai et al., 2008). The role of the serpinel gene is to synthesize plasminogen 353 activator inhibitor 1 (PAI-1), and the mutation increases production (Morange et al., 354 2007). High concentration of PAI-1 leads to inhibit plasmin from fibrinolysis, causing to 355 accumulate clots in veins (Heit MD, 2013; Morange et al., 2007; Kazuo Miyashita et al., 356 2012). The allelic discrimination of KASP-PCR of this mutation showed that ~40% of 357 samples are heterozygote, while 14.4% were detected as homozygote mutant (Figure 7. 358 7). In total, 54% of patients carried PAI-1 variation. Yapikajis et al., (2012) conducted a 359 genotyping study using blood samples from a healthy Greek population, and 49% were 360 found mutated. A case-control study was performed to define the correlation between

361 high concentration of PAI-1 and developing ischemic stroke in young Indian patients.

362 Akhter et al., (2017) found that 62% of young Indian patients have PAI-1 SNP. Xu et

al., (2016) found that ~46% of chronic obstructive pulmonary disease through Chinese

Han patients were heterozygote, while ~14% were homozygote mutants. These results

- are in line with the current findings (Table 1).
- 366

367 Conclusion

368 A gene panel covering five thrombophilia associated mutations (Serpine 1, MTHFR1, 369 MTHFR2, Factor V Leiden, and Factor II) was developed based on the KASP-PCR 370 assay to diagnose thrombophilia genetic risk factors. The variety of diagnostic tests, the 371 unreliability of clinical judgment, and a delayed diagnosis could lead to illnesses that 372 may increase mortality and morbidity. In addition, molecular-based analyses are highly 373 costly and time-consuming to obtain accurate results compared to the KASP-PCR assay. 374 The KASP-PCR assay is a cost-effective (~2-3 dollar per reaction), timesaving (3-4 375 hours), non-invasive, accurate, and highly sensitive. In this study, we obtained a clear 376 allelic discrimination for all samples tested to screen SNPs related to thrombophilia. 377 Rather than expensive and time-consuming approaches, the current assay enables the 378 cost-effective advantage of the KASP-PCR assay, which reduces the diagnostic cost 379 with a fast and convenient way. After clinical validation and approval, it can be used in 380 hospitals, research centers, and diagnostic laboratories to determine the genetic 381 susceptibility of individuals to thrombosis and also for research purposes.

382

Acknowledgment This study is funded by the Deanship of Graduate Studies under
project number 2023-003-IRMC. The figures are created with BioRender.com.

385

386 Compliance with Ethical Standards

387 **Conflict of interest** The authors declare that they have no conflict of interest.

388

389 Authors' contributions

390 HT and RA conceptualized the study. RA and HT conducted the experiments. RA, and

391 HT wrote the manuscript. AA, TA, MA, HA, NA, AIA identified the patients and

392 provided the samples. TU revised and commented on the manuscript.

394

396 **References**

397

- •Wang X, Fu J, Li Q, Zeng D. Geographical and Ethnic Distributions of the MTHFR
 C677T, A1298C and MTRR A66G Gene Polymorphisms in Chinese Populations:
- 400AMeta-Analysis.PLoSOne.2016Apr18;11(4):e0152414.doi:40110.1371/journal.pone.0152414.PMID: 27089387;PMCID: PMC4835080.
- 402 Akhter MS, Biswas A, Abdullah SM, Behari M, Saxena R. The Role of PAI-1 4G/5G
 403 Promoter Polymorphism and Its Levels in the Development of Ischemic Stroke in
- 404 Young Indian Population. Clin Appl Thromb Hemost. 2017 Nov;23(8):1071-1076.
- 405 doi: 10.1177/1076029617705728. Epub 2017 May 1. PMID: 28460568.
- 406 Algasham, A., Ismail, H., Dowaidar, М., & Settin, A. A. (2011).407 Methylenetetrahydrofolate Reductase (MTHFR) and Angiotensin Converting 408 Enzyme (ACE) Gene Polymorphisms among Saudi Population from Qassim 409 Region. International Journal of Health Sciences, 5(2 Suppl 1), 3.
- Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, Mahjoub T.
 Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single
 nucleotide polymorphisms among Arabs. J Thromb Thrombolysis. 2005
 Dec;20(3):163-8. doi: 10.1007/s11239-005-3550-4. PMID: 16261289.
- Alvarez-Fernandez, A., Bernal, M. J., Fradejas, I., Martin Ramírez, A., Md Yusuf, N.
 A., Lanza, M., ... & Rubio, J. M. (2021). KASP: a genotyping method to rapid
 identification of resistance in Plasmodium falciparum. Malaria Journal, 20(1), 1-8.
- Al-Zoubi, N., Alrabadi, N., Kheirallah, K., & Alqudah, A. (2021). Prevalence and
 Multiplicity of Thrombophilia Genetic Polymorphisms of FV, MTHFR, F II, and
 PAI-I: A Cross-Sectional Study on a Healthy Jordanian Population. International

Journal of General Medicine, 5323-5332.

- 420
- 421 Badireddy M, Mudipalli VR. Deep Venous Thrombosis Prophylaxis. 2022 Aug 22. In:
 422 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
 423 PMID: 30521286.
- 424 Balta, G. Ü. N. A. Y., Altay, C., & Gurgey, A. Y. T. E. M. İ. Z. (2003). Prevalence of
- PAI-1 gene 4G/5G genotype in Azerbaijan and Kyrgyzstan populations: literature
 review. Journal of Thrombosis and Haemostasis, 1(4), 858-859.
- 427 Bezgin T, Kaymaz C, Akbal Ö, Yılmaz F, Tokgöz HC, Özdemir N. Thrombophilic 428 Gene Mutations in Relation to Different Manifestations of Venous

429 Thromboembolism: A S	Single Tertiary	Center Study. Clin	Appl Thromb Hemost.
--------------------------	-----------------	--------------------	---------------------

- 430 2018 Jan;24(1):100-106. doi: 10.1177/1076029616672585. Epub 2016 Oct 11.
- 431 PMID: 27729560; PMCID: PMC6714624.
- Dajani, R., Fatahallah, R., Dajani, A., Al-Shboul, M., & Khader, Y. (2012). Prevalence
 of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in
 Chechans, a genetically isolated population in Jordan. Molecular biology reports,
 39, 9133-9138.
- Dajani, R., Fathallah, R., Arafat, A., AbdulQader, M. E., Hakooz, N., Al-Motassem, Y.,
 & El-Khateeb, M. (2013). Prevalence of MTHFR C677T single nucleotide
 polymorphism in genetically isolated populations in Jordan. Biochemical genetics,
 51, 780-788.
- 440 Dean L. Methylenetetrahydrofolate Reductase Deficiency. 2012 Mar 8 [updated 2016
 441 Oct 27]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman
 442 BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda
 443 (MD): National Center for Biotechnology Information (US); 2012–. PMID:
 444 28520345.
- Djordjevic V, Stankovic M, Brankovic-Sreckovic V, Rakicevic L, Damnjanovic T,
 Antonijevic N, Radojkovic D. Prothrombotic genetic risk factors in stroke: a
 possible different role in pediatric and adult patients. Clin Appl Thromb Hemost.
 2012 Nov;18(6):658-61. doi: 10.1177/1076029611432136. Epub 2012 Jan 23.
 PMID: 22275392.
- Dölek, B., Eraslan, S., Eroğlu, S., Kesim, B. E., Ulutin, T., Yalçıner, A., ... &
 Gözükirmızı, N. (2007). Molecular analysis of factor V Leiden, factor V Hong
 Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and
 A1298C mutations related to Turkish thrombosis patients. Clinical and Applied
 Thrombosis/Hemostasis, 13(4), 435-438.
- 455 Golestani, A., Rahimi, A., Moridi, N. et al. Association of factor V Leiden R506Q, 456 FXIIIVal34Leu, and MTHFR C677T polymorphisms with acute myocardial 457 infarction. 23. Egypt J Med Hum Genet 118 (2022). 458 https://doi.org/10.1186/s43042-022-00330-9.
- Gowda, M.S., Zucker, M.L., Vacek, J.L. et al. Incidence of Factor V Leiden in Patients
 with Acute Myocardial Infarction. J Thromb Thrombolysis 9, 43–45 (2000).
 https://doi.org/10.1023/A:1018652429633

Graydon, J. S., Claudio, K., Baker, S., Kocherla, M., Ferreira, M., Roche-Lima, A., ... &

463	Ruaño, G. (2019). Ethnogeographic prevalence and implications of the 677C> T
464	and 1298A> C MTHFR polymorphisms in US primary care populations.
465	Biomarkers in Medicine, 13(8), 649-661.
466	He, Chunlin, John Holme, and Jeffrey Anthony. "SNP genotyping: the KASP assay."
467	Crop breeding. Humana Press, New York, NY, 2014. 75-86.
468	Hickey, S. E., Curry, C. J., & Toriello, H. V. (2013). ACMG Practice Guideline: lack of
469	evidence for MTHFR polymorphism testing. Genetics in Medicine, 15(2), 153-
470	156.
471	Isordia-Salas, I., Leaños-Miranda, A., Sainz, I. M., Reyes-Maldonado, E., & Borrayo-
472	Sánchez, G. (2009). Association of the plasminogen activator inhibitor-1 gene
473	4G/5G polymorphism with ST elevation acute myocardial infarction in young
474	patients. Revista Española de Cardiología (English Edition), 62(4), 365-372.
475	John A. Heit, 14 - Thrombophilia: Clinical and Laboratory Assessment and
476	Management, Editor(s): Craig S. Kitchens, Craig M. Kessler, Barbara A. Konkle,
477	Consultative Hemostasis and Thrombosis (Third Edition), W.B. Saunders, 2013,
478	Pages 205-239, ISBN 9781455722969, https://doi.org/10.1016/B978-1-4557-
479	2296-9.00014-2.
480	(https://www.sciencedirect.com/science/article/pii/B9781455722969000142)
481	Joint, W. H. O. (1995). Inherited thrombophilia: report of a Joint WHO (No.
482	WHO/HGN/ISTH/WG/95.5. Unpublished). World Health Organization.
483	Kazuo Miyashita, Show Nishikawa, Masashi Hosokawa, Chapter 29 - Therapeutic
484	Effect of Fucoxanthin on Metabolic Syndrome and Type 2 Diabetes, Editor(s):
485	Debasis Bagchi, Nair Sreejayan, Nutritional and Therapeutic Interventions for
486	Diabetes and Metabolic Syndrome, Academic Press, 2012, Pages 367-379, ISBN
487	9780123850836, https://doi.org/10.1016/B978-0-12-385083-6.00029-2.
488	Kujovich, J. L. (2018). Factor V Leiden thrombophilia.
489	Linnemann, B., & Hart, C. (2019). Laboratory diagnostics in thrombophilia.
490	Hämostaseologie, 39(01), 049-061.
491	Madkhaly F, Alshaikh A, Alkhail HA, Alnounou R, Owaidah T. Prevalence of positive
492	factor V Leiden and prothrombin mutations in samples tested for thrombophilia in
493	Saudi Arabia. Am J Blood Res. 2021 Jun 15;11(3):255-260. PMID: 34322288;
494	PMCID: PMC8303010.

Makhoul M, Rambla C, Voss-Fels KP, Hickey LT, Snowdon RJ, Obermeier C.
Overcoming polyploidy pitfalls: a user guide for effective SNP conversion into
KASP markers in wheat. Theor Appl Genet. 2020 Aug;133(8):2413-2430. doi:
10.1007/s00122-020-03608-x. Epub 2020 Jun 4. PMID: 32500260; PMCID:
PMC7360542.

- Morange, P. E., Saut, N., Alessi, M. C., Yudkin, J. S., Margaglione, M., Di Minno, G.,
 ... & Juhan-Vague, I. (2007). Association of plasminogen activator inhibitor
 (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and
 metabolic parameters: the HIFMECH study. Arteriosclerosis, thrombosis, and
 vascular biology, 27(10), 2250-2257.
- Nikolopoulos, G., Bagos, P., Tsangaris, I., Tsiara, C., Kopterides, P., Vaiopoulos, A.,
 Kapsimali, V., Bonovas, S. & Tsantes, A. (2014). The association between
 plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G
 polymorphism, and myocardial infarction: a Mendelian randomization metaanalysis. Clinical Chemistry and Laboratory Medicine (CCLM), 52(7), 937-950.
 https://doi.org/10.1515/cclm-2013-1124
- 511 Özbek, N., Ataç, F. B., Verdi, H., & Kayıran, S. M. (2003). Purpura fulminans in a child
 512 with combined heterozygous prothrombin G20210A and factor V Leiden
 513 mutations. Annals of hematology, 82, 118-120.
- Raptopoulou, A., Michou, V., Mourtzi, N., Papageorgiou, E. G., Voyiatzaki, C.,
 Tsilivakos, V., ... & Bei, T. A. (2022). Large Scale screening for factor V Leiden
 (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek
 population. Health Science Reports, 5(4), e457.
- Sabbagh, A. S., Mahfoud, Z., Taher, A., Zaatari, G., Daher, R., & Mahfouz, R. A.
 (2008). High prevalence of MTHFR gene A1298C polymorphism in Lebanon.
 Genetic Testing, 12(1), 75-80.
- Settin, A. A., Alghasham, A., Ali, A., Dowaidar, M., & Ismail, H. (2012). Frequency of
 thrombophilic genetic polymorphisms among Saudi subjects compared with other
 populations. Hematology, 17(3), 176-182.
- Tsai, S. J., Hong, C. J., Liou, Y. J., Yu, Y. W. Y., & Chen, T. J. (2008). Plasminogen
 activator inhibitor-1 gene is associated with major depression and antidepressant
 treatment response. Pharmacogenetics and genomics, 18(10), 869-875.

Xu X, Wang H, Li H, Cui X, Zhang H. SERPINE1 -844 and -675 polymorphisms and
chronic obstructive pulmonary disease in a Chinese Han population. Journal of
International Medical Research. 2016;44(6):1292-1301.
doi:10.1177/0300060516664270

- Xu, Y., Duan, L., Wong, D. W. K., Wong, T. Y., & Liu, J. (2016). Semantic
 reconstruction-based nuclear cataract grading from slit-lamp lens images. In
 Medical Image Computing and Computer-Assisted Intervention-MICCAI 2016:
 19th International Conference, Athens, Greece, October 17-21, 2016, Proceedings,
 Part III 19 (pp. 458-466). Springer International Publishing.
- Yang, S., Yu, W., Wei, X., Wang, Z., Zhao, Y., Zhao, X., ... & Zhang, X. (2020). An
 extended KASP-SNP resource for molecular breeding in Chinese cabbage
 (Brassica rapa L. ssp. pekinensis). Plos one, 15(10), e0240042.
- Yapijakis, C., Serefoglou, Z., & Voumvourakis, C. (2015). Common Gene
 Polymorphisms Associated with Thrombophilia. In (Ed.), Thrombosis,
 Atherosclerosis and Atherothrombosis New Insights and Experimental Protocols.
 IntechOpen. https://doi.org/10.5772/61859
- Yapijakis, C., Serefoglou, Z., Nixon, A. M., Vylliotis, A., Ragos, V., & Vairaktaris, E.
 (2012). Prevalence of thrombosis-related DNA polymorphisms in a healthy Greek
 population. in vivo, 26(6), 1095-1101.
- Yousef, A. M., Shomaf, M., Berger, S., Ababneh, N., Bobali, Y., Ali, D., ... & Ismail, S.
 (2013). Allele and genotype frequencies of the polymorphic
 methylenetetrahydrofolate reductase and colorectal cancer among Jordanian
 population. Asian Pacific Journal of Cancer Prevention, 14(8), 4559-4565.
- 550 Zhang, Y., Liang, D., Huang, H., Yang, Z., Wang, Y., Yu, Y., ... & Xiao, W. (2020).
- 551 Development and application of KASP assays for rapid screening of 8 genetic 552 defects in Holstein cattle. Journal of Dairy Science, 103(1), 619-624.